Pregnancy rate in women with adenomyosis undergoing fresh or frozen embryo transfer cycles following gonadotropin-releasing hormone agonist treatment
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To determine the preferred regimen for women with adenomyosis undergoing in vitro fertilization (IVF), we compared the IVF outcomes of fresh embryo transfer (ET) cycles with or without gonadotropin-releasing hormone (GnRH) agonist pretreatment and of frozen-thawed embryo transfer (FET) cycles following GnRH agonist treatment. METHODS: This retrospective study included 241 IVF cycles of women with adenomyosis from January 2006 to January 2012. Fresh ET cycles without (147 cycles, group A) or with (105 cycles, group B) GnRH agonist pretreatment, and FET cycles following GnRH agonist treatment (43 cycles, group C) were compared. Adenomyosis was identified by using transvaginal ultrasound at the initial workup and classified into focal and diffuse types. The IVF outcomes were also subanalyzed according to the adenomyotic region. RESULTS: GnRH agonist pretreatment increased the stimulation duration (11.5±2.1 days vs. 9.9±2.0 days) and total dose of gonadotropin (3,421±1,141 IU vs. 2,588±1,192 IU), which resulted in a significantly higher number of retrieved oocytes (10.0±8.2 vs. 7.9±6.8, p=0.013) in group B than in group A. Controlled ovarian stimulation for freezing resulted in a significantly higher number of retrieved oocytes (14.3±9.2 vs. 10.0±8.2, p=0.022) with a lower dose of gonadotropin (2,974±1,112 IU vs. 3,421±1,141 IU, p=0.037) in group C than in group B. The clinical pregnancy rate in group C (39.5%) tended to be higher than those in groups B (30.5%) and A (25.2%) but without a significant difference. CONCLUSION: FET following GnRH agonist pretreatment tended to increase the pregnancy rate in patients with adenomyosis. Further large-scale prospective studies are required to confirm this result.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathology and physiopathology of adenomyosis
Bergeron, C., Amant, F., & Ferenczy, A. (2006) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2006.01.016 · Cited by 359 · cited 1×
“Adenomyosis is histologically defined as the presence of ectopic endometrial islets deep in the myometrium surrounded by a reactive hypertrophic myometrium [8].”
BackgroundKitawaki, J., Noguchi, T., Amatsu, T., Maeda, K., Tsukamoto, K., Yamamoto, T., Fushiki, S., Osawa, Y., & Honjo, H. (1997) · Biology of Reproduction · doi:10.1095/biolreprod57.3.514 · Cited by 305
HOXA10 expression is decreased in endometrium of women with adenomyosis
Fischer, C. P., Kayisili, U., & Taylor, H. S. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.09.060 · Cited by 133 · cited 2×
“Adenomyosis is associated with several conditions that could interfere with natural conception [1-3].”
Background
Cited by
Diagnosing adenomyosis: an integrated clinical and imaging approach
Chapron, C., Vannuccini, S., Santulli, P., Abrão, M. S., Carmona, F., Fraser, I. S., Gordts, S., Guo, S.-W., Just, P.-A., Noël, J.-C., et al. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmz049 · Cited by 416
Recent advances in understanding and managing adenomyosis
Vannuccini, S., & Petraglia, F. (2019) · F1000Research · doi:10.12688/f1000research.17242.1 · Cited by 291
Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis
Younes, G., & Tulandi, T. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.06.025 · Cited by 268
Role of medical therapy in the management of uterine adenomyosis
Vannuccini, S., Luisi, S., Tosti, C., Sorbi, F., & Petraglia, F. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.01.013 · Cited by 231
Dueholm, M. (2017) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1111/aogs.13158 · Cited by 113
The Effect of Uterine Adenomyosis on IVF Outcomes: a Systematic Review and Meta-analysis
Cozzolino, M., Tartaglia, S., Pellegrini, L., Troiano, G., Rizzo, G., & Petraglia, F. (2022) · Reproductive Sciences · doi:10.1007/s43032-021-00818-6 · Cited by 102
Conservative management of uterine adenomyosis: medical vs. surgical approach
Stratopoulou, C. A., Donnez, J., & Dolmans, M.-M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10214878 · Cited by 62
“A more recent study, however, failed to identify a significant difference in clinical pregnancy rates between 241 treated and untreated infertile adenomyosis patients in this category [89].”
ResultGonadotropin-releasing hormone antagonist (linzagolix): A new therapy for uterine adenomyosis
Donnez, O., & Donnez, J. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.04.017 · Cited by 58
Metadata
- Authors
- Park, C. W., Choi, M. H., Yang, K. M., & Song, I. O.
- Venue
- Clinical and Experimental Reproductive Medicine
- Published
- 2016
- Volume
- 43
- Issue
- 3
- Pages
- 169
- ISSN
- 2093-8896 (ISSN-L)
- 2233-8233
- 2233-8241
- OpenAlex
- W2526935097
- Cited by
- 135
- References
- 3
- FWCI
- 9.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.